Table 3 Efficacy outcomes
Outcome | Vemurafenib (N = 46) |
|---|---|
Confirmed BORR, n (%) [95% CI] | 24 (52.2) [36.95–67.11] |
Complete response | 1 (2.2) |
Partial response | 23 (50.0) |
Stable disease | 21 (45.7) |
Progressive disease | 1 (2.2) |
Disease control rate | 45 (97.8) |
Median time to confirmed response, months (range) | 1.84 (1.7–5.7) |
Median duration of confirmed response, months (95% CI) | 9.13 (7.39–NE) |
Median PFS, months (95% CI) | 8.25 (5.65–10.94) |
PFS, % (95% CI) | |
6 months | 58.7 (44.5–72.9) |
1 year | 33.4 (19.5–47.4) |
Median OS, months (95% CI) | 13.54 (12.19–NE) |
OS, % (95% CI) | |
6 months | 89.1 (80.1–98.1) |
1 year | 64.6 (50.7–78.6) |